Skip to main content
SpringerLink
Log in

Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model

  • Protocol
  • First Online:
Gene Therapy of Cancer

Part of the book series: Methods in Molecular Biology ((MIMB,volume 2521))

Abstract

Genetic vaccination using naked plasmid DNA is an immunization strategy both against infectious diseases and cancer.

In order to improve efficacy of DNA vaccines, particularly in large animals and humans, different strategies have been pursued. These vaccination strategies are based on different application routes, schedules and coexpression of immunomodulatory molecules as adjuvants. Our mouse tumor model offers the possibility to investigate Her2/neu DNA vaccines in different settings, that is, intramuscular or intradermal application with or without coexpression of adjuvants. The immunogenicity of predicted peptides for Her2/neu specific memory T cells were screened and confirmed after intramuscular and intradermal application. Protection from tumor growth in tumor challenge experiments and both T cell and humoral immune responses against Her2/neu peptides are used as surrogate parameters for vaccine efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Sharma O, Sultan AA, Ding H et al (2020) A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 11(2413):585354. https://doi.org/10.3389/fimmu.2020.585354

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Paston SJ, Brentville VA, Symonds P et al (2021) Cancer vaccines, adjuvants, and delivery systems. Front Immunol 12(985):627932. https://doi.org/10.3389/fimmu.2021.627932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. ElTanbouly MA, Noelle RJ (2021) Rethinking peripheral T cell tolerance: checkpoints across a T cell’s journey. Nat Rev Immunol 21(4):257–267

    Article  CAS  Google Scholar 

  4. Schumacher TN, Scheper W, Kvistborg P (2019) Cancer Neoantigens. Annu Rev Immunol 37:173–200

    Article  CAS  Google Scholar 

  5. Bernhard H, Salazar L, Schiffman K et al (2002) Vaccination against the HER-2/neu oncogenic protein. Endocr Relat Cancer 9:33–44

    Article  CAS  Google Scholar 

  6. Ko BK, Kawano K, Murray JL et al (2003) Clinical studies of vaccines targeting breast cancer. Clin Cancer Res 9:3222–3234

    CAS  PubMed  Google Scholar 

  7. Milani A, Sangiolo D, Montemurro F et al (2013) Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives. Ann Oncol 24:1740–1748

    Article  CAS  Google Scholar 

  8. Cavallo F, Offringa R, van der Burg SH et al (2006) Vaccination for treatment and prevention of cancer in animal models. Adv Immunol 90:175–213

    Article  CAS  Google Scholar 

  9. Ladjemi MZ, Jacot W, Chardes T et al (2010) Anti-HER2 vaccines: new prospects for breast cancer therapy. Cancer Immunol Immunother 59:1295–1312

    Article  CAS  Google Scholar 

  10. Nguyen-Hoai T, Baldenhofer G, Sayed Ahmed MS et al (2012) CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model. Cancer Gene Ther 19:69–76

    Article  CAS  Google Scholar 

  11. Nguyen-Hoai T, Baldenhofer G, Ahmed MS et al (2012) CCL19 (ELC) improves TH1-polarized immune responses and protective immunity in a murine Her2/neu DNA vaccination model. J Gene Med 14:128–137

    Article  CAS  Google Scholar 

  12. Nguyen-Hoai T, Hohn O, Vu MD et al (2012) CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC. Cancer Gene Ther 19:880–887

    Article  CAS  Google Scholar 

  13. Nguyen-Hoai T, Kobelt D, Hohn O et al (2012) HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: gene gun is superior to jet injector in inducing CTL responses and protective immunity. Onco Targets Ther 1:1537–1545

    Google Scholar 

  14. Curigliano G, Locatelli M, Fumagalli L et al (2009) Immunizing against breast cancer: a new swing for an old sword. Breast 18(Suppl 3):51–54

    Article  Google Scholar 

  15. Mittendorf EA, Clifton GT, Holmes JP et al (2012) Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute clinical trials group study I-01 and I-02. Cancer 118:2594–2602

    Article  CAS  Google Scholar 

  16. Curigliano G, Spitaleri G, Pietri E et al (2006) Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 17:750–762

    Article  CAS  Google Scholar 

  17. Piechocki MP, Ho YS, Pilon S et al (2003) Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 171:5787–5794

    Article  CAS  Google Scholar 

  18. Piechocki MP, Pilon SA, Wei WZ (2001) Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367–3374

    Article  CAS  Google Scholar 

  19. Cho HI, Niu G, Bradley N et al (2008) Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors. Cancer Immunol Immunother 57:1695–1703

    Article  CAS  Google Scholar 

  20. Astolfi A, Rolla S, Nanni P et al (2005) Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario. Cancer Immunol Immunother 54:599–610

    Article  CAS  Google Scholar 

  21. Aurisicchio L, Peruzzi D, Conforti A et al (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of toll-like receptor 9. Clin Cancer Res 15:1575–1584

    Article  CAS  Google Scholar 

  22. Anderson BW, Kudelka AP, Honda T et al (2000) Induction of determinant spreading and of Th1 responses by in vitro stimulation with HER-2 peptides. Cancer Immunol Immunother 49:459–468

    Article  CAS  Google Scholar 

  23. Amici A, Smorlesi A, Noce G et al (2000) DNA vaccination with full-length or truncated neu induces protective immunity against the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Gene Ther 7:703–706

    Article  CAS  Google Scholar 

  24. Chang SY, Lee KC, Ko SY et al (2004) Enhanced efficacy of DNA vaccination against Her- 2/neu tumor antigen by genetic adjuvants. Int J Cancer 111:86–95

    Article  CAS  Google Scholar 

  25. Norell H, Poschke I, Charo J et al (2010) Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial. J Transl Med 8:53. https://doi.org/10.1186/1479-5876-8-53

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pupa SM, Iezzi M, Di Carlo E et al (2005) Inhibition of mammary carcinoma development in HER-2/neu transgenic mice through induction of autoimmunity by xenogeneic DNA vaccination. Cancer Res 65:1071–1078

    Article  CAS  Google Scholar 

  27. Smorlesi A, Papalini F, Pierpaoli S et al (2008) HER2/neu DNA vaccination for breast tumors. Methods Mol Biol 423:473–485

    Article  CAS  Google Scholar 

  28. Wei WZ, Shi WP, Galy A et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748–754

    Article  CAS  Google Scholar 

  29. Pilon SA, Piechocki MP, Wei WZ (2001) Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167:3201–3206

    Article  CAS  Google Scholar 

  30. Lindencrona JA, Preiss S, Kammertoens T et al (2004) CD4+ T cell-mediated HER-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 109:259–264

    Article  CAS  Google Scholar 

  31. Kiessling R, Wei WZ, Herrmann F et al (2002) Cellular immunity to the Her2/neu protooncogene. Adv Cancer Res 85:101–144

    Article  CAS  Google Scholar 

  32. Nguyen-Hoai T, Pham-Duc M, Gries M et al (2016) CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model. Cancer Gene Ther 23:162–167

    Article  CAS  Google Scholar 

  33. Walther W, Stein U, Fichtner I et al (2005) Nonviral jet-injection gene transfer for efficient in vivo cytosine deaminase suicide gene therapy of colon carcinoma. Mol Ther 12(6):1176–1184. https://doi.org/10.1016/j.ymthe.2005.07.700

    Article  CAS  PubMed  Google Scholar 

  34. Nagata Y, Furugen R, Hiasa A (1997) Peptides derived from a wild-type murine proto-oncogene c-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 159:1336–1343

    CAS  PubMed  Google Scholar 

  35. Correa I, Plunkett T (2001) Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 3:399–403

    Article  CAS  Google Scholar 

  36. Vertuani S, Sette A, Sidney J (2004) Improved immunogenicity of an immunodominant epitope of the HER-2/neu protooncogene by alterations of MHC contact residues. J Immunol 172:3501–3508

    Article  CAS  Google Scholar 

  37. Westermann J, Nguyen-Hoai T, Mollweide A et al (2004) Flt-3 ligand as adjuvant for DNA vaccination augments immune responses but does not skew TH1/TH2 polarization. Gene Ther 11:1048–1056

    Article  CAS  Google Scholar 

  38. Wonderlich J, Shearer G, Livingstone A et al (2006) UNIT 3.11 induction and measurement of cytotoxic T lymphocyte activity. Curr Protoc Immunol Chapter 3:Unit 3.11. https://doi.org/10.1002/0471142735.im0311s72

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Experimental and Clinical Research Center, Charité - Universitätsmedizin Berlin, Berlin, Germany

    Tam Nguyen-Hoai

  2. Robert Koch Institute, Berlin, Germany

    Oliver Hohn

  3. Charité - Universitätsmedizin Berlin and Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

    Antonio Pezzutto

  4. Department Hematology, Oncology and Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany

    Jörg Westermann

Authors
  1. Tam Nguyen-Hoai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oliver Hohn
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Pezzutto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jörg Westermann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tam Nguyen-Hoai .

Editor information

Editors and Affiliations

  1. Max-Delbrück-Center for Molecular Medicine, Berlin, Berlin, Germany

    Wolfgang Walther

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature

About this protocol

Check for updates. Verify currency and authenticity via CrossMark

Cite this protocol

Nguyen-Hoai, T., Hohn, O., Pezzutto, A., Westermann, J. (2022). Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model. In: Walther, W. (eds) Gene Therapy of Cancer. Methods in Molecular Biology, vol 2521. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-2441-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-0716-2441-8_7

  • Published:

  • Publisher Name: Humana, New York, NY

  • Print ISBN: 978-1-0716-2440-1

  • Online ISBN: 978-1-0716-2441-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation